Multiple epitopes of the human ovarian cancer antigen 14C1 recognised by human IgG antibodies: their potential in immunotherapy
1991
Human Antibodies Against Ovarian Cancer Antigen 14C1
publication
Evidence: moderate
Author Information
Author(s): G. Gallagher, F. Al-Azzawi, L.P. Walsh, G. Wilson, J. Handley
Primary Institution: University of Strathclyde
Hypothesis
Can human antibodies against the 14C1 antigen be used for immunotherapy in ovarian cancer?
Conclusion
The study suggests that the 14C1 antigen may be a promising target for immunotherapy in ovarian cancer.
Supporting Evidence
- The 14C1 antigen was found to be highly restricted to ovarian epithelial tumors.
- Antibodies against 14C1 were shown to promote the killing of ovarian cancer cells in vitro.
- At least three distinct epitopes on the 14C1 antigen were identified.
Takeaway
Scientists found a special protein in ovarian cancer that can be targeted by human antibodies to help fight the disease.
Methodology
The study involved preparing human IgG-secreting cell lines from ovarian cancer patients and testing their ability to recognize the 14C1 antigen.
Participant Demographics
Patients with ovarian cancer were involved in the study.
Want to read the original?
Access the complete publication on the publisher's website